Detailed results from Cytokinetics, Inc.'s Phase III SEQUOIA-HCM trial testing its cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM) have led some cardiologists to conclude the drug could have a competitive edge over Bristol Myers Squibb’s rival myosin inhibitor Camzyos (mavacamten).
Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say
CEO Robert Blum Talked To Scrip
The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.
More from Cardiovascular
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.
• By
Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.
More from Therapy Areas
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.